Expert Discussion: Building Unique Networks and Partnerships to Bring Novel Therapies to Remote Patients

Arleigh Robertson McCurdy; Nicole Laferriere

doi:10.58931/cht.2025.4s0570

Authors

Arleigh Robertson McCurdy, MHA, MD, FRCPC University of Ottawa, Ottawa, ON, The Ottawa Hospital, Ottawa, ON, Ottawa Hospital Research Institute, Ottawa, ON
Nicole Laferriere, MD, Ph.D, FRCPC Northern Ontario School of Medicine, Sudbury, ON, Thunder Bay Regional Cancer Program, Thunder Bay, ON, Regional Cancer Care Northwest, Thunder Bay, ON, Canadian Hematology Society, Ottawa, ON

DOI:

https://doi.org/10.58931/cht.2025.4s0570

Abstract

Novel, highly effective therapies for multiple myeloma are raising hopes, while also adding complexity to treatment decisions and care management. Recently, Canadian Hematology Today sat down with two Canadian experts and discussed what the availability of novel therapies means for patients, and how clinical leaders are coordinating care to improve access for patients in Northern Ontario.

Author Biographies

Arleigh Robertson McCurdy, MHA, MD, FRCPC, University of Ottawa, Ottawa, ON, The Ottawa Hospital, Ottawa, ON, Ottawa Hospital Research Institute, Ottawa, ON

Dr. Arleigh Robertson McCurdy is an Associate Professor in the Faculty of Medicine at the University of Ottawa, Lead of the Multiple Myeloma Program at The Ottawa Hospital, and a Clinician Investigator at The Ottawa Hospital Research Institute. Her clinical research is focused on multiple myeloma and related disorders. She is a member of the Canadian Cancer Trials Group Myeloma Committee, the International Myeloma Working Group, and she is currently the Treasurer on the Canadian Myeloma Research Group Board of Directors.

Nicole Laferriere, MD, Ph.D, FRCPC, Northern Ontario School of Medicine, Sudbury, ON, Thunder Bay Regional Cancer Program, Thunder Bay, ON, Regional Cancer Care Northwest, Thunder Bay, ON, Canadian Hematology Society, Ottawa, ON

Dr. Laferriere completed an HBSc degree in Medical Laboratory Science at Lakehead University and a PhD in Cell Biology at the University of Ottawa. She completed her undergraduate medical degree at McMaster University, then attended the University of Ottawa for Internal Medicine and Hematology Residency. She has been a full time Hematologist in the Regional Cancer Program since 2005. From 2015–2023 she held the appointment of Chief of Oncology. She is the Medical Director and Systemic Therapy Regional Quality Lead for Cancer Care Northwest. She is an Associate Professor at NOSM and Past President of the Canadian Hematology Society. She is the recipient of the College of Physicians and Surgeons of Ontario (CPSO) 2020 Council award.

Expert Discussion: Building Unique Networks and Partnerships to Bring Novel Therapies to Remote Patients

Authors

DOI:

Abstract

Author Biographies

Arleigh Robertson McCurdy, MHA, MD, FRCPC, University of Ottawa, Ottawa, ON, The Ottawa Hospital, Ottawa, ON, Ottawa Hospital Research Institute, Ottawa, ON

Nicole Laferriere, MD, Ph.D, FRCPC, Northern Ontario School of Medicine, Sudbury, ON, Thunder Bay Regional Cancer Program, Thunder Bay, ON, Regional Cancer Care Northwest, Thunder Bay, ON, Canadian Hematology Society, Ottawa, ON

Downloads

Published

How to Cite

Issue

Section

License

Summary

Open Access

Licence